Standpoint Research Starts Kite Pharma (KITE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Kite Pharma Provides Update on KTE-C19 Clinical Trial
August 17, 2015 8:00 AM EDTKite KTE-C19 Trial on Track to Advance to Pivotal Phase 2
Kite to Host Conference Call and Webcast on August 17, 2015 at 9:00am Eastern Time
SANTA MONICA, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to... More
Kite Pharma Provides Update on KTE-C19 Clinical Trial
August 17, 2015 8:00 AM EDTKite KTE-C19 Trial on Track to Advance to Pivotal Phase 2
Kite to Host Conference Call and Webcast on August 17, 2015 at 9:00am Eastern Time
SANTA MONICA, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to... More
